Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib

Multiple Myeloma Clinical Trial

— ADHOMY2  

Official title:

Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05184595
• Other study ID #: 2020-A00605-34
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2022
• Est. completion date: October 30, 2024

Study information

• Verified date: December 2021
• Source: Central Hospital, Nancy, France
• Contact: Andreia CARVALHO DE FREITAS
• Phone: 0383859305
• Email: a.carvalhodefreitas[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Carfilzomib is administered in treatment of Multiple Myeloma intravenously on two consecutive days, each week for three weeks (days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (days 17 to 28). With COVID pandemic, the investigators had to limit patient visits to the hospital. The treatment protocols were modified by switching to weekly injections of carfilzomib according to the PLEIADES and ARROW 2 studies. Considering the frequency of intravenous (IV) administration, home-based chemotherapy in Hospital-at-Home (HaH) setting is an attractive and suitable alternative to standard hospital-based chemotherapy in Outpatient-Hospital (OH), and is expected to provide both cost-savings for the Health Insurance (HI) and improvement in patient quality of life (QoL). The purpose of the study is to assess the cost-utility of home-based compared to hospital-based carfilzomib administration in multiple myeloma. The investigators are also planning on assessing healthcare resource utilization and related costs, adverse and intercurrent events, and patients' quality of life and satisfaction, for each strategy.

Description:

All participants receive the first cycle of treatment in OH. They are then randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services. For the HaH group, the first injection of each cycle is delivered in OH. The rest of the cycle is delivered at home by HaH after a clinical examination (by nurse or general practitionner). Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after the end of treatment. Participants we leave the protocol prematurely in case of treatment failure, toxicity or if participant ask to. For those patients, the end of study visit will be done one month after ending treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: October 30, 2024
• Est. primary completion date: March 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Age > 18 years
• relapsed multiple myeloma, at least one prior line of treatment
• treatment with carfilzomib validated in a multidisciplinary consultation meeting and accepted by the patient
• The patient accepts mixed management and benefits from the support of his/her family and friends (see ANAES 2003 criteria). If the patient does not have a caregiver, he/she can still participate in the research and the absence of a caregiver will be collected.
• Patient capable of adhering to care (cf. ANAES 2003 criteria)
• Patient affiliated to a social security system or beneficiary of such a system.
• Patient having received full information on the organization of the research and having signed his or her informed consent

Exclusion Criteria:

• Person with a contraindication to carfilzomib
• Women of childbearing age who do not have effective contraception
• Persons referred to in articles L. 1121-5, L. 1121-7; L1121-8 and L1122-1-2 of the Public Health Code
• Pregnant woman, parturient or nursing mother
• Minor (not emancipated)
• Adult person under a legal protection measure (guardianship, curatorship, safeguard of justice)
• A person of full age who is unable to express his or her consent

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Other:
• Carfilzomib delivered in OH only
Patients receive the whole treatment en OH.
• Carfilzomib delivered in OH and HaH combined
Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incremental cost-utility ratio (ICUR) expressed in euros per QALY.	Incremental cost-utility ratio (ICUR) of home-based compared to hospital-based carfilzomib administration in multiple myeloma, expressed in euros per QALY according to EQ-5D-5L questionnaire (EuroQOL 5 dimensions 5 levels) from 0 to 1 (1 being the best state with no problem)	Up to 20 months
Primary	Differences of quality of life in cancer patients between each group	Difference of quality of life according to EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer Quality of life Questionnaire with 30 questions, answer from 1 to 4, 1 being the best state with no problem)	Up to 20 months
Primary	Differences of quality of life in myeloma patients between each group	Difference of quality of life according to EORTC QLQ-MY20 questionnaire (European Organisation for Research and Treatment of Cancer Quality of life Questionnaire with 20 questions related to myeloma symptoms, answer from 1 to 4, 1 being the best state with no problem)	Up to 20 months
Primary	Cost of care	Cost for Health Insurance by patients, at the end of treament: Total costs per patient and average cost per injection	Up to 20 month
Secondary	Healthcare resource utilization	Rate of emergency visits to the Emergency Room; Rate of emergency consultation with the attending physician; Call rate in the referring center (Nancy Hospital)	Up to 20 months
Secondary	Adverse events related to myeloma treatment	Rate of nosocomial infection, neuropathy, digestive disorders; Unscheduled hospitalization rates	Up to 20 months
Secondary	Patients and caregivers' satisfaction	- Patients' and Caregivers' Satisfaction Scores at the end of the treatment according to questionnaires with (opened and closes-questions) : 4 questions for OH group 9 questions for OH and HaH group 7 questions for caregiver	Up to 20 months